Atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist that is in development for the preventive treatment of migraine, is likely to be co-administered with the analgesic medications acetaminophen or naproxen.

In this phase 1, open-label, drug–drug interaction study, atogepant overall exposure (area under the plasma drug concentration-time curve) was similar when administered alone or co-administered with acetaminophen or naproxen; peak atogepant plasma concentration, time to peak plasma concentration, and atogepant half-life were also similar when co-administered with acetaminophen or naproxen.

Co-administration of atogepant with acetaminophen or naproxen appeared safe and no clinically significant drug–drug interactions were observed.